ריברוקסבאן
הערות שוליים

↑  Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Tiemo J. Bandel, Horst Beckmann, Eva Muehlhofer, Frank Misselwitz, William Geerts, Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty, New England Journal of Medicine 358, 2008-06-26, עמ' 2765–2775 doi: 10.1056/NEJMoa0800374 (באנגלית)
↑  Ajay K. Kakkar, Benjamin Brenner, Ola E. Dahl, Bengt I. Eriksson, Patrick Mouret, Jim Muntz, Andrea G. Soglian, Akos F. Pap, Frank Misselwitz, Sylvia Haas, RECORD2 Investigators, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, Lancet (London, England) 372, 2008-07-05, עמ' 31–39 doi: 10.1016/S0140-6736(08)60880-6 (באנגלית)
↑  Michael R. Lassen, Walter Ageno, Lars C. Borris, Jay R. Lieberman, Nadia Rosencher, Tiemo J. Bandel, Frank Misselwitz, Alexander G. G. Turpie, RECORD3 Investigators, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, The New England Journal of Medicine 358, 2008-06-26, עמ' 2776–2786 doi: 10.1056/NEJMoa076016 (באנגלית)
↑  Alexander G. G. Turpie, Michael R. Lassen, Bruce L. Davidson, Kenneth A. Bauer, Michael Gent, Louis M. Kwong, Fred D. Cushner, Paul A. Lotke, Scott D. Berkowitz, Tiemo J. Bandel, Alice Benson, Frank Misselwitz, William D. Fisher, RECORD4 Investigators, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, Lancet (London, England) 373, 2009-05-16, עמ' 1673–1680 doi: 10.1016/S0140-6736(09)60734-0 (באנגלית)
↑  Alexander G. G. Turpie, Revisiting RECORD4, Lancet (London, England) 400, 2022-12-10, עמ' 2047–2048 doi: 10.1016/S0140-6736(22)02422-9 (באנגלית)
↑  Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism (PE) With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
↑  Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis (DVT) Without Symptomatic Pulmonary Embolism: Einstein-DVT Evaluation
↑  Once-Daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study
↑  Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
↑  Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E. Singer, Werner Hacke, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Jonathan P. Piccini, Richard C. Becker, Christopher C. Nessel, John F. Paolini, Scott D. Berkowitz, Keith A. A. Fox, Robert M. Califf, ROCKET AF Investigators, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, The New England Journal of Medicine 365, 2011-09-08, עמ' 883–891 doi: 10.1056/NEJMoa1009638 (באנגלית)
↑  A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
↑  Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott, Jean-Pierre Bassand, Deepak L. Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A.A. Fox, Shinya Goto, Sabina A. Murphy, Alexei N. Plotnikov, David Schneider, Xiang Sun, Freek W.A. Verheugt, C. Michael Gibson, Rivaroxaban in Patients with a Recent Acute Coronary Syndrome, New England Journal of Medicine 366, 2012-01-05, עמ' 9–19 doi: 10.1056/NEJMoa1112277 (באנגלית)
↑  MAGELLAN - Multicenter, Randomized, Parallel Group Efficacy Superiority Study in Hospitalized Medically Ill Patients Comparing Rivaroxaban with Enoxaparin
↑  Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study, 2016-08-03, עמ' טבלה 12 (באנגלית)
↑  Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)
1 2  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
↑  Stuart J. Connolly, John W. Eikelboom, Jackie Bosch, Gilles Dagenais, Leanne Dyal, Fernando Lanas, Kaj Metsarinne, Martin O'Donnell, Anthony L. Dans, Jong-Won Ha, Alexandr N. Parkhomenko, Alvaro A. Avezum, Eva Lonn, Liu Lisheng, Christian Torp-Pedersen, Petr Widimsky, Aldo P. Maggioni, Camilo Felix, Katalin Keltai, Masatsugu Hori, Khalid Yusoff, Tomasz J. Guzik, Deepak L. Bhatt, Kelley R. H. Branch, Nancy Cook Bruns, Scott D. Berkowitz, Sonia S. Anand, John D. Varigos, Keith A. A. Fox, Salim Yusuf, COMPASS investigators, Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial, Lancet (London, England) 391, 2018-01-20, עמ' 205–218 doi: 10.1016/S0140-6736(17)32458-3 (באנגלית)
↑  Faiez Zannad, Stefan D. Anker, William M. Byra, John G.F. Cleland, Min Fu, Mihai Gheorghiade, Carolyn S.P. Lam, Mandeep R. Mehra, James D. Neaton, Christopher C. Nessel, Theodore E. Spiro, Dirk J. van Veldhuisen, Barry Greenberg, Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease, New England Journal of Medicine 379, 2018-10-04, עמ' 1332–1342 doi: 10.1056/NEJMoa1808848 (באנגלית)
↑  באייר, קסרלטו 2.5, 5, 10, 20 מג, מדריך לרופא (עמ' 7), באתר משרד הבריאות, ‏31.01.2021
↑  קסרלטו באתר "אינפומד"
↑  "אירוע מוחי", אתר "שירותי בריאות כללית"
↑  קסרלטו 10 מ"ג - עלון לצרכן עם התוויות לשימוש, אגף הרוקחות במשרד הבריאות
↑  to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery Bayer's Xarelto Approved in Canada
↑  Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
↑  Rivaroxaban approved in Europe for AF and DVT treatment
↑  FDA Approves Oral Anticoagulant Rivaroxaban for DVT Prevention at Surgery
↑  2016 ESC Guidelines for the management of atrial fibrillation,European Heart Journal
↑  Effectiveness And Safety Of Reduced Dose Non-Vitamin K Antagonist Oral Anticoagulants In Patients Without Severe Renal Impairment,Value in Health Volume 19, Issue 3, May 2016, Pages A2
↑  פרדיגמת טיפול חדשה בהפחתת אירועים קרדיו-וסקולריים, המתבססת על תוצאות מחקר COMPASS
↑  S. Galliazzo, M. P. Donadini, W. Ageno, Antidotes for the direct oral anticoagulants: What news?, Thrombosis Research 164 Suppl 1, 2018-04, עמ' S119–S123 doi: 10.1016/j.thromres.2018.01.006 (באנגלית)
↑  "New blood thinner 'antidote' to help doctors move past warfarin". Reuters (באנגלית). 2015-12-23. נבדק ב-2023-01-13.
↑  Stefan Oelrich, President of the Pharmaceuticals Division, Capital Markets Day 2021 (עמ' 3), www.bayer.com, ‏10/03/2021 (באנגלית)
↑  "Bayer, Johnson & Johnson settle more than 25,000 lawsuits over blood thinner Xarelto for $775 million". Washington Post (באנגלית אמריקאית). ISSN 0190-8286. נבדק ב-2023-01-13.
↑  Alexander G. G. Turpie, Michael R. Lassen, Bruce L. Davidson, Kenneth A. Bauer, Michael Gent, Louis M. Kwong, Fred D. Cushner, Paul A. Lotke, Scott D. Berkowitz, Tiemo J. Bandel, Alice Benson, Frank Misselwitz, William D. Fisher, RECORD4 Investigators, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, Lancet (London, England) 373, 2009-05-16, עמ' 1673–1680 doi: 10.1016/S0140-6736(09)60734-0
↑  Maryanne Demasi, Rivaroxaban: Lancet opens investigation into anticlotting drug trial after BMJ report, BMJ (Clinical research ed.) 379, 2022-12-30, עמ' o3071 doi: 10.1136/bmj.o3071
הבהרה: המידע בוויקיפדיה נועד להעשרה בלבד ואינו מהווה ייעוץ רפואי.
המבנים הכימיים של לינזוליד (למעלה) ושל ריברוקסבאן (למטה). המבנה המשותף מסומן בכחול.